FindMyKOL
Clinical trialNCT05332899RecruitingPhase 1Interventional

Influenza Human Challenge Model

NCT05332899 is a phase 1 interventional trial sponsored by Emory University. As of 21 Nov 2026, it is recruiting participants. It studies Influenza Virus Type A H3N2 Challenge in Influenza. The registry lists an enrollment of 80 participants at 2 sites in 1 country. The registry lists a start date of 24 May 2022 and a primary completion date of 31 Dec 2027. One of its registered investigators has a FindMyKOL profile.

SponsorEmory University →Enrollment80Influenza
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT05332899
FieldValue
Registry IDNCT05332899
StatusRecruiting
PhasePhase 1
Study typeInterventional trial
Lead sponsorEmory University
Enrollment80
Registered sites2
Countries1
ConditionsInfluenza
DrugsInfluenza Virus Type A H3N2 Challenge
Start24 May 2022
Primary completion31 Dec 2027
Study completion31 Dec 2027
Last update posted27 Mar 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study examines how the immune system responds to the flu virus (H3N2) during and after infection and how the flu virus is transmitted in the environment. The study will used a flu virus called the H3N2 influenza challenge virus which was produced specifically for use in clinical research in controlled conditions. The study will also assess the safety of the H3N2 influenza challenge in healthy subjects. Mild to moderate symptoms are expected based on previous studies with this strain of influenza.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Georgia, United States2 sites, 2 recruiting

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgia: 2 sites, 2 recruitingGA2HawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Influenza Virus Type A H3N2 Challenge
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT05332899

Each answer restates registry values shown on this page.

What is NCT05332899?

NCT05332899 is a phase 1 interventional trial sponsored by Emory University. It studies Influenza Virus Type A H3N2 Challenge in Influenza.

Is NCT05332899 recruiting?

As of 21 Nov 2026, it is recruiting participants. 2 of its 2 sites list their own status as recruiting.

Who leads NCT05332899?

The registry names Nadine Rouphael, MD (principal investigator, Emory University) as the overall official.

Where does NCT05332899 run?

The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT05332899 study?

The registered drug and biological interventions are Influenza Virus Type A H3N2 Challenge.

When is NCT05332899 expected to complete?

The registry lists a primary completion date of 31 Dec 2027 and a study completion date of 31 Dec 2027. The sponsor last updated the record on 27 Mar 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.